[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Yueyang Integrated Medicine Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":297},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,69,93,114,137,156,177,197,216,238,259,279],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100638982","electroacupuncture-for-insomnia-in-patients-with-chronic-sciatica-due-to-lumbar-disc-herniation-a-randomized-controlled-trial-100638982",false,"NCT07576348","Electroacupuncture for Insomnia in Patients With Chronic Sciatica Due to Lumbar Disc Herniation: a Randomized Controlled Trial","Inclusion Criteria:\n\nParticipants will be eligible if they meet all of the following criteria:\n\n1. Aged 18-75 years, of either sex;\n2. Diagnosis with lumbar disc herniation accompanied by unilateral chronic sciatica (disease duration ≥ 3 months);\n3. Experiencing moderate to severe radiating leg pain (below the knee), defined as a Numerical Rating Scale (NRS) score ≥ 4 at screening within the past 24 h;\n4. Diagnosis of chronic insomnia, with a Pittsburgh Sleep Quality Index (PSQI) total score \\> 7;\n5. Onset or exacerbation of insomnia temporally associated with the onset or worsening of sciatica symptoms;\n6. Willing to participate and able to provide written informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following criteria are met:\n\n1. Spinal or structural conditions: lumbar spinal stenosis, spondylolisthesis, vertebral fracture, spinal infection (e.g., tuberculosis), or tumor;\n2. Surgical indications: cauda equina syndrome, conus medullaris syndrome, or other conditions requiring urgent surgical intervention;\n3. Severe systemic diseases: unstable cardiovascular, hepatic, renal, respiratory, or hematological disorders, or metabolic conditions that may significantly affect study outcomes (e.g., uncontrolled diabetes or thyroid disease);\n4. Neurological or psychiatric disorders: major neurological diseases (e.g., epilepsy, Parkinson's disease, dementia, multiple sclerosis) or severe psychiatric disorders (e.g., schizophrenia);\n5. Clinically significant depression or anxiety, defined as Patient Health Questionnaire-9 (PHQ-9) ≥ 10 and\u002For Generalized Anxiety Disorder-7 (GAD-7) ≥ 10;\n6. Other primary sleep disorders, including obstructive sleep apnea, narcolepsy, or restless legs syndrome;\n7. Use of centrally acting medications: regular use (≥ 3 days\u002Fweek within 4 weeks prior to enrolment) of medications affecting the central nervous system (e.g., opioids, sedative-hypnotics, antidepressants) without an adequate washout period (≥ 2 weeks or longer depending on drug half-life);\n8. Irregular sleep patterns, including night shift work (≥ 2 times\u002Fweek between 22:00-06:00) or highly irregular sleep-wake cycles;\n9. Pregnancy or lactation;\n10. History of substance abuse or dependence;\n11. Lumbar spine surgery or interventional procedures within the past 3 months;\n12. History of acupuncture treatment;\n13. Implanted electronic devices (e.g., pacemakers) or metal implants at acupuncture sites;\n14. Participation in another clinical trial within the past 3 months;\n15. Severe sensory or cognitive impairment affecting assessment compliance;\n16. Any other condition deemed by investigators to compromise safety or data integrity.","ALL","18 Years","75 Years",{"count":19,"type":20},114,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if electroacupuncture can improve sleep in people with chronic sciatica caused by lumbar disc herniation. It will also assess the safety of this treatment. The main questions it aims to answer are whether electroacupuncture improves sleep quality and whether it reduces pain and improves daily function. Researchers will compare electroacupuncture to a sham treatment, which looks like real acupuncture but has little or no therapeutic effect, to determine its effectiveness. Participants will be randomly assigned to receive electroacupuncture or sham treatment, will receive treatment three times per week for four weeks, and will complete questionnaires about their sleep, pain, and daily activities.",[26,27,28],"Sciatica","Lumbar Disc Herniation","Insomnia","NOT_YET_RECRUITING","2026-05-04",{"date":32,"type":33},"2026-05-08","ACTUAL",{"date":35,"type":20},"2026-05",{"date":37,"type":20},"2027-03",{"name":39,"class":40},"Shanghai Yueyang Integrated Medicine Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100634360","phase-2-peiyuan-guben-tongluo-ointment-for-elderly-sarcopenia-100634360","NCT07538674","Peiyuan Guben Tongluo Ointment for Elderly Sarcopenia","A Randomized, Double-Blind Clinical Study of Peiyuan Guben Tongluo Ointment in the Treatment of Elderly Sarcopenia (Spleen-Kidney Deficiency Syndrome) With Two Internal and External Controls","Inclusion Criteria:\n\n* Patients aged ≥ 60 years and ≤ 80 years, regardless of gender; ② Patients meeting the diagnostic criteria for sarcopenia in the elderly according to both traditional Chinese medicine (TCM) and Western medicine;\n\n  * Patients meeting the TCM diagnostic criteria for Spleen-Kidney Deficiency Syndrome;\n\n    * Able to take oral medications, willing to comply with the study intervention protocol, able to attend follow-up visits on time, and have signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with quadriplegia, long-term bedridden status, zero muscle strength due to severe cerebrovascular accident, muscle atrophy caused by various factors, or inability to perform activities of daily living;\n\n  * Patients with unclear consciousness, aphasia, delirium, inability to respond, or impaired time, location and orientation due to senile or vascular dementia;\n\n    * Patients with severe mental illness, depressive state, or receiving relevant psychotropic medication; ④ Patients complicated with tumors, severe infections, gastrointestinal bleeding, hepatic and renal insufficiency, cardiac insufficiency, or other diseases affecting nutritional status; ⑤ Patients with hypersensitivity to the study drugs; patients who have received or are receiving traditional Chinese medicine treatment within the past 1 month; patients who have received medications affecting muscle contraction\u002Frelaxation within the past 1 month.","60 Years","80 Years",{"count":51,"type":20},60,[53],"PHASE2","With the agarose concentrating group of Peiyuan Guben Tongluo Ointment set as the parallel control and an external control established simultaneously, this study aimed to evaluate the increases from baseline in DXA-measured limb muscle mass after 12 weeks of medication in elderly sarcopenia patients treated with the Ejiao concentrating group of Peiyuan Guben Tongluo Ointment.",[56],"Sarcopenia in Elderly",[56,58,59],"Deficiency of Spleen and Kidney Yin","Peiyuan Guben Tongluo Ointment","2026-04-15",{"date":62,"type":33},"2026-04-20",{"date":64,"type":20},"2026-04",{"date":66,"type":20},"2028-12-31",{"name":39,"class":40},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":77,"targetDuration":79,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100626318","cross-sectional-study-for-an-ocular-imaging-based-predictive-model-of-inflammatory-skin-diseases-grounded-in-traditional-chinese-medicine-100626318","NCT07434076","Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine","Inclusion Criteria:\n\nFor patients with inflammatory skin disease:\n\nClinical diagnosis of one of the three target inflammatory skin diseases (psoriasis, atopic dermatitis, or urticaria).\n\nAge ≥ 18 and ≤ 65 years, any sex.\n\nUnderstands and signs informed consent.\n\nFor healthy controls:\n\nDo not meet diagnostic criteria for any of the three inflammatory skin diseases above.\n\nAge ≥ 18 and ≤ 65 years, any sex.\n\nUnderstands and signs informed consent.\n\nExclusion Criteria:\n\nFor patients with inflammatory skin disease:\n\nExclude any subject meeting any of the following:\n\nRefusal to undergo examinations.\n\nPresence of acute\u002Factive infectious ocular disease (e.g., viral keratoconjunctivitis).\n\nCorneal perforation or high-risk perforation where contact procedures cause severe photophobia, eye pain, inability to keep eyes open or fixate.\n\nNystagmus or other conditions that prevent fixation.\n\nPupillary non-dilation (e.g., posterior synechiae) that precludes fundus imaging.\n\nSevere eyelid lesions (e.g., marked swelling, ectropion, entropion) that prevent globe exposure.\n\nParticipation in other clinical trials within the previous 3 months or concurrent participation in other interventional studies.\n\n* Healthy control - exclusion criteria\n\nExclude any subject meeting any of the following:\n\nPresence of other skin diseases that could affect study assessments (e.g., atopic dermatitis, urticaria, scabies).\n\nRefusal to undergo examinations.\n\nAcute\u002Factive infectious ocular disease (e.g., viral keratoconjunctivitis).\n\nCorneal perforation or high-risk perforation that causes severe photophobia, eye pain, inability to keep eyes open or fixate during contact procedures.\n\nNystagmus or other reasons preventing fixation.\n\nPupillary non-dilation (e.g., posterior synechiae) that prevents fundus imaging.\n\nParticipation in other clinical studies within the previous 3 months or currently participating in other clinical trials.",true,"65 Years",{"count":78,"type":20},950,"1 Day","OBSERVATIONAL","This study is a cross-sectional, observational investigation designed to develop and validate a noninvasive ocular imaging-based predictive model for major inflammatory skin diseases, including psoriasis, atopic dermatitis, and urticaria. Grounded in Traditional Chinese Medicine (TCM) ocular diagnostic theory and integrated with advanced computer vision techniques, the study aims to establish objective, quantifiable biomarkers derived from scleral and bulbar conjunctival images.\n\nApproximately 950 participants (patients with psoriasis, atopic dermatitis, urticaria, and healthy controls) will be recruited from a tertiary academic hospital. Standardized high-resolution ocular images will be collected alongside comprehensive clinical, demographic, and comorbidity data. Disease severity will be assessed using validated clinical scoring systems (e.g., PASI, EASI, UAS7, DLQI).\n\nImage analysis will combine traditional radiomics feature extraction with deep learning architectures, including a Vision State-Space (VMamba) module for global-local feature representation and a Multi-Gate Mixture-of-Experts (MMoE) framework for multi-task learning. The model is designed to simultaneously perform disease classification and predict comorbidity risks (such as metabolic syndrome, hepatic insulin resistance, and recurrence risk).\n\nPrimary outcomes include characterization of ocular feature patterns associated with inflammatory skin diseases. Secondary outcomes include correlations between ocular image-derived features and clinical severity indices. Model performance will be evaluated using ROC curves, AUC, calibration analysis, and decision curve analysis.\n\nThis study aims to provide an objective, digitalized, and clinically applicable ocular biomarker framework to support early diagnosis, risk stratification, and comorbidity screening in inflammatory skin diseases.",[83,84],"Psoriasis","Atopic Dermatitis","2026-02-19",{"date":87,"type":33},"2026-02-25",{"date":89,"type":20},"2026-03-05",{"date":91,"type":20},"2028-05-25",{"name":39,"class":40},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":99,"targetDuration":101,"studyType":80,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":68},"100619963","research-on-the-extraction-of-tongue-and-facial-diagnosis-features-of-psoriasis-vulgaris-in-traditional-chinese-medicine-and-its-correlation-with-laboratory-indicators-100619963","NCT07351448","Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators","Inclusion Criteria:\n\n* Inclusion criteria for the non-psoriasis subjects: (1) Those who do not meet the Western medical diagnostic criteria for psoriasis; （2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form; Inclusion criteria for the psoriasis blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood stasis syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nInclusion criteria for the psoriasis non-blood stasis syndrome group: (1) Those who meet the Western medical diagnostic criteria for psoriasis and whose TCM syndrome classification belongs to blood heat syndrome\u002Fblood dryness syndrome; (2) No gender restrictions; 18 years old ≤ age ≤ 65 years old; (3) Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Due to various reasons, the collected tongue and facial images may be unclear or cannot be successfully monitored and analyzed; (2) For those subjects whose facial makeup or tongue coating is applied, the information obtained from tongue and facial diagnosis may be inaccurate.",{"count":100,"type":20},450,"2 Weeks","Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients. Its clinical features include erythema, papules, covered with varying scales, a long course of disease, and recurrent attacks. According to traditional Chinese medicine, psoriasis is mainly characterized by blood heat syndrome, blood stasis syndrome and blood dryness syndrome, accounting for more than 90% of all syndrome types. The TCM syndrome differentiation and treatment of psoriasis also attach great importance to the transformation and evolution of TCM syndrome types. For instance, the three syndrome types of blood heat syndrome, blood stasis syndrome and blood dryness syndrome are not static and can transform into each other. For example, blood heat syndrome can develop into blood dryness syndrome as the disease progresses, blood dryness syndrome can transform into blood stasis syndrome, and blood stasis syndrome can also transform into blood heat syndrome or blood dryness syndrome. Observation is an important diagnostic method in traditional Chinese medicine. The images of tongue and face diagnosis contain a lot of important clinical information. They can objectively reflect the prosperity and decline of qi and blood in the human body, the nature of diseases, the depth of the lesion location, the prognosis of the disease, and can also reflect the physiological and pathological changes of the body. In recent years, significant progress has been made in the research of digital and intelligent technologies for tongue and facial diagnosis. Introducing objective indicators such as tongue diagnosis, facial diagnosis and pulse diagnosis into the evaluation research of diseases has become a hot topic. This project, by analyzing the clinical tongue and facial image data of patients with psoriasis vulgaris and combining it with clinical laboratory indicators, fuses and analyzes the characteristic parameters of patients' tongue and facial diagnosis with blood biochemical indicators, metabolomics and other data. This is helpful to reveal the disease occurrence pattern of patients with blood stasis type psoriasis and construct a diagnostic model for blood stasis syndrome of psoriasis. At the same time, it provides a powerful decision support tool for clinical practice and also helps deepen our understanding of the complex process of the occurrence of blood stasis type psoriasis, thereby providing a solid scientific basis for formulating precise diagnostic and treatment strategies.",[104,105,106],"Psoriasis (PsO)","Traditional Chinese Medicine (TCM)","Diagnosis","2026-01-12",{"date":109,"type":33},"2026-01-20",{"date":109,"type":20},{"date":112,"type":20},"2027-09-30",{"name":39,"class":40},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":68},"100593203","phase-2-exploration-of-the-efficacy-and-mechanism-of-galantamine-an-extract-from-lycoris-aurea-in-treating-ischemic-stroke-100593203","NCT07003386","Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke","Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke Based on the Neurovascular Unit","Inclusion Criteria:\n\n* Aged \\> 18 years and \\\u003C 85 years, regardless of gender\n* Meeting the diagnostic criteria for ischemic stroke in Western medicine\n* Meeting the diagnostic criteria for stroke (Zhongfeng) in Traditional Chinese Medicine (TCM)\n* Diagnosis of acute ischemic stroke within 72h of symptom onset\n* A score of 4-25 points on the National Institute of Health Stroke Scale (NIHSS)\n* First onset of the disease, or no severe sequelae related to previous onset\n* The patient and their legal guardian voluntarily sign the informed consent form for the study\n\nExclusion Criteria:\n\n* Confirmed by cranial imaging examination to have diseases causing similar symptoms such as brain tumors, encephalitis, and brain abscesses; or confirmed to have hemorrhagic cerebral infarction,epidural hematoma,intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.\n* Patients with severe abnormalities of liver and kidney function (liver function: alanine aminotransferase \\[ALT\\] \\>2 times the upper limit of normal \\[ULN\\]; renal function: creatinine \\[Cr\\]\\>1.5 times the upper limit of normal \\[ULN\\])\n* Elderly patients with physical weakness or patients complicated with infection\n* Patients with a history of mental illness or dementia\n* Patients with other severe organ or systemic diseases, accompanied by malignant tumors in any organ or system, or undergoing anti-tumor treatment, with an expected survival time of \\\u003C 6 months\n* A significant history of drug or alcohol abuse\n* Women who test positive for blood human chorionic gonadotropin (HCG) (i.e., HCG ≥ 5 mIU\u002FmL) during pregnancy screening, plan to become pregnant during the trial, or are breastfeeding\n* Patients who are currently participating in other clinical trials or have participated in other clinical trials within the past 1 month\n* Patients who are currently using other cholinesterase inhibitor drugs or have used other cholinesterase inhibitor drugs within the past 3 months\n* Patients with epilepsy, hyperkinesis, mechanical intestinal obstruction, bronchial asthma, angina pectoris, bradycardia, or glaucoma\n* Patients with contraindications to brain magnetic resonance imaging (MRI) examination, such as patients with implanted cardiac pacemakers, patients with implanted artificial joints or orthopedic plates, patients with claustrophobia, etc","85 Years",{"count":123,"type":20},66,[53,125],"PHASE3","Although mechanical thrombectomy or thrombolytic therapy for large vessels can achieve a revascularization rate (TICI ≥2b) of over 90%, 30-50% of patients still exhibit poor functional outcomes. This phenomenon of \"ineffective reperfusion\" suggests that microcirculatory dysfunction plays a decisive role in post-stroke neural injury. Therefore, it is necessary to combine brain protection strategies with microcirculatory reperfusion therapy to improve the functional prognosis of stroke patients.Increasing cerebral blood flow (CBF) and neurovascular unit (NVU)-based cerebral protection are current hotspots in the emergency treatment of stroke.\n\nGalantamine, extracted from Lycoris aurea (a traditional Chinese medicinal herb), is an acetylcholinesterase inhibitor (AChEI) that has been widely recognized for improving cerebral blood flow and modulating inflammatory responses in ischemic stroke (IS).\n\nTherefore, the applicant will conduct an internationally compliant, randomized controlled clinical study with routine treatment to evaluate the efficacy of galantamine in the treatment of acute cerebral infarction. This project will conduct a comprehensive assessment of the drug's efficacy from multiple aspects, including improvements in stroke-related outcomes, Traditional Chinese Medicine (TCM) syndrome manifestations, cognitive function, cerebral blood flow, and inflammatory factors.",[128],"Acute Ischemic Stroke AIS","RECRUITING","2025-09-15",{"date":132,"type":33},"2025-09-16",{"date":130,"type":20},{"date":135,"type":20},"2028-09-30",{"name":39,"class":40},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100586990","efficacy-of-acupuncture-in-the-treatment-of-moderate-to-severe-atopic-dermatitis-100586990","NCT06922565","Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis","Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis: a Multicentre Randomised Sham-controlled Clinical Trial","Inclusion Criteria:\n\n* Meet the diagnostic criteria for moderate to severe atopic dermatitis;\n\n  * Age ≥18 and ≤75 years old gender is not limited; ③ Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4; ④ Voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who are in the acute onset of the disease and have erosions exudates and secondary infections;\n\n  * Patients who have participated in other clinical studies in the past 3 months or are participating in other clinical studies; ③ Patients with severe haematological diseases (e.g. platelet count \\\u003C50×109 \u002FL) and other serious diseases that may affect operation and efficacy;\n\n    * Current systematic use of glucocorticosteroids discontinued for less than 7 days; immunosuppressants (cyclosporine methotrexate tretinoin etc.) discontinued for less than 1 month; dulprevirizumab discontinued for less than 1 month JAK inhibitors discontinued for less than 2 weeks;\n\n      * Women who are pregnant or breastfeeding; ⑥ Patients with a history of acupuncture treatment.",{"count":145,"type":20},110,[23],"This study used a multicentre parallel three-armed randomised sham-controlled clinical trial methodology in order to objectively and normatively assess the efficacy of acupuncture on Quchi the Sea of Blood the Foot Sanli and the Sanyinjiao in the treatment of moderate-to-severe atopic dermatitis so as to obtain high-level evidence-based medical evidence.\n\nThis study adopts a multi-centre, parallel, three-armed, randomized, sham-controlled clinical trial method, and will be conducted at Yueyang Hospital of Integrative Medicine affiliated with Shanghai University of Traditional Chinese Medicine, Huashan Hospital affiliated with Fudan University, and Seventh People's Hospital affiliated with Shanghai University of Traditional Chinese Medicine. Eligible patients with moderate-to-severe AD will be divided into three groups using stratified block randomisation in the ratio of 2:2:1: the acupuncture group, the sham-acupuncture group and the waitlisted control group. The total observation period is 9 weeks, including a 1-week introduction period, a 4-week treatment period and a 4-week follow-up period.",[84],"2025-04-03",{"date":151,"type":33},"2025-04-10",{"date":149,"type":20},{"date":154,"type":20},"2026-06-30",{"name":39,"class":40},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":162,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100576872","construction-of-a-psoriasis-and-psoriatic-arthritis-diagnostic-model-based-on-multidimensional-nail-information-100576872","NCT06790940","Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information","Inclusion Criteria:\n\n\\-\n\nInclusion criteria for patients with psoriasis:\n\n1. Previous or first-time diagnosis o psoriasis; if previously diagnosed, no restrictions on prior treatments;\n2. Age ≥ 18 and ≤ 80 years, with no gender restrictions;\n3. Consent to participate in this study and sign an informed consent form.\n\nInclusion criteria for non-psoriasis control subjects:\n\n(1) Patients who visit for other non-psoriasis skin conditions such as eczema or acne, and are confirmed by dermatologists not to have psoriasis; (3) Age ≥ 18 and ≤ 80 years, with no gender restrictions; (4) Consent to participate in this study and sign an informed consent form.\n\n\\-\n\nExclusion criteria for patients with psoriasis:\n\n1. Those with unsuitable nail conditions for collection: patients with amputated fingers due to trauma or other reasons, and patients with any nail that is severely broken and cannot be effectively collected.\n2. Patients with severe mental illness or cognitive impairment, lacking personal decision-making capacity, and unsuitable for participation in clinical research.\n3. Patients with severe systemic diseases.\n4. Patients with a history of malignant tumors, as well as those with primary or secondary immunodeficiency and hypersensitivity.\n5. Patients whom the researchers deem unsuitable for participation in this study for other reasons.\n\nExclusion criteria for non-psoriasis subjects:\n\n1. Those with unsuitable nail conditions for collection: patients with amputated fingers due to trauma or other reasons, and patients with any nail that is severely broken and cannot be effectively collected.\n2. Patients with severe mental illness or cognitive impairment, lacking personal decision-making capacity, and unsuitable for participation in clinical research.\n3. Patients with severe systemic diseases.\n4. Patients with a history of malignant tumors, as well as those with primary or secondary immunodeficiency and hypersensitivity.\n5. Patients whom the researchers deem unsuitable for participation in this study for other reasons.",{"count":163,"type":20},310,"Psoriasis is a globally prevalent chronic relapsing skin disease, characterized by its long duration and tendency to relapse. In addition to skin symptoms, it can also affect nails and joints, leading to pathological features such as pitting, leukonychia, red lunula, or severe nail dystrophy. Some patients with psoriasis may develop psoriatic arthritis. Psoriatic arthritis (PsA) is a chronic relapsing musculoskeletal disease, characterized by psoriatic skin lesions accompanied by axial and peripheral joint damage, and often associated with characteristic manifestations of psoriatic nails. These nail changes typically indicate more severe disease and poorer prognosis. However, current diagnostic methods largely depend on the experience and professional knowledge of clinicians, which are subjective and uncertain. Moreover, histopathological examination is invasive and can cause additional pain and inconvenience to patients.\n\nTo develop an effective, convenient, and non-invasive early diagnostic tool for psoriasis, our research team has conducted in-depth studies in the field of psoriasis-related diagnosis and predictive models. We have successfully developed a predictive model for psoriatic arthritis, including six key predictive factors: history of joint swelling, history of arthritis, history of swelling and pain in fingers or toes, nail involvement, genital involvement, and a history of long-term local use of corticosteroids. Clinicians can effectively assess the risk of psoriatic arthritis by obtaining information about these six factors from patients. The paper \"Early detection of psoriatic arthritis in patients with psoriasis: construction of a multifactorial prediction model\" was published in Front. Immunol (DOI: 10.3389\u002Ffimmu.2024.1426127).\n\nRaman spectroscopy is a rapid, non-invasive molecular vibration detection method that has shown great potential in medical diagnostics. Studies have shown that Raman spectroscopy can distinguish normal and abnormal tissues at the molecular level and has been proven feasible in nail testing. For psoriasis, a disease that causes significant nail changes, Raman spectroscopy offers unique advantages.\n\nBased on this background, our project will conduct a prospective observational study on psoriasis and psoriatic arthritis using multidimensional nail data. We will integrate Raman spectroscopy data of nails and multidimensional clinical information and apply artificial intelligence algorithms to develop a new diagnostic tool for psoriasis and psoriatic arthritis. This tool aims to improve the accuracy and efficiency of diagnosis, providing strong support for the early detection and precise treatment of psoriasis and psoriatic arthritis.",[104,166,167,168],"Psoriatic Arthritis","Palmoplantar Pustulosis (PPP)","Plaque Psoriasis","2025-01-23",{"date":171,"type":33},"2025-01-24",{"date":173,"type":20},"2025-01-20",{"date":175,"type":20},"2026-12-01",{"name":39,"class":40},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":121,"enrollmentInfo":184,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":68},"100561594","hepatic-safety-of-statin-use-in-neurology-inpatients-100561594","NCT06592196","Hepatic Safety of Statin Use in Neurology Inpatients","A Retrospective Study on the Hepatic Safety of Statin Use in Neurology Inpatients","Inclusion Criteria:\n\n1. Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.\n2. Age ≥18 and ≤85 years old, both sexes.\n3. Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.\n\nExclusion Criteria:\n\n1. Incomplete medical history.\n2. 1 days ≤ patients with \\\u003C 7 days of prior statin use.\n3. Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).",{"count":185,"type":20},2000,"This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.",[188],"Statin Adverse Reaction","2024-09-11",{"date":191,"type":33},"2024-09-19",{"date":193,"type":33},"2024-08-10",{"date":195,"type":20},"2024-12-10",{"name":39,"class":40},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":204,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":68},"100560655","multimodal-high-frequency-ultrasound-based-study-of-plaque-psoriasis-severity-index-100560655","NCT06579976","Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index","Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index：a Prospective Cohort Study","Inclusion Criteria:\n\n1. Patients who meet the medical criteria for plaque psoriasis\n2. Those who voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with other types of psoriasis\n2. Those with other active medical conditions that may affect assessment\n3. During a severe uncontrollable acute or chronic local or systemic infection\n4. Those with severe mental illness, cognitive impairment, and incapacity for personal behavior that makes them unsuitable to participate in a clinical study\n5. Other reasons the investigator considers unsuitable for participation in this study",{"count":205,"type":20},45,"Psoriasis (PsO) is a common chronic relapsing inflammatory disease, induced by a combination of genetic and environmental effects, which seriously affects the quality of life of patients.Psoriasis Area and Severity Index（PASI score ） ，as the most common method used by clinicians to assess the severity of psoriasis and the effectiveness of treatment, has the disadvantage of being subjective and superficial.We are therefore committed to establishing an objective, real-time, repeatable, non-invasive, microscopic assessment using high-frequency ultrasound. This study will use high-frequency ultrasound to detect the patient's lesion site and the 2cm site next to the lesion once, and the study will continue to recruit for 6 months.",[168],"2024-08-29",{"date":210,"type":33},"2024-08-30",{"date":212,"type":20},"2024-09-01",{"date":214,"type":20},"2025-05-01",{"name":39,"class":40},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":75,"sex":15,"minAge":223,"maxAge":17,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":68},"100554027","acupuncture--neuromodulation-for-post-stroke-aphasia-100554027","NCT06493747","Acupuncture + Neuromodulation for Post-Stroke Aphasia","Efficacy and Mechanism Study of Acupuncture Combined With Neuromodulation Technology for Post-Stroke Aphasia Based on Multimodal Functional Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Diagnosed with aphasia following stroke according to both traditional Chinese and Western medical standards; first-time stroke in the left cerebral hemisphere (including cerebral infarction and cerebral hemorrhage), with unilateral lesion.\n2. Age between 25 and 75 years old, disease course of at least 1 month, no gender restrictions.\n3. Right-handed as tested by the Edinburgh Handness Inventory, with at least an elementary school education level.\n4. Retention of basic cognitive functions such as attention, memory, and visuospatial skills (Non-language-based Cognitive Assessment, NLCA score \\>70).\n5. Aphasia confirmed by initial assessment with the Western Aphasia Battery (WAB); an Aphasia Quotient (AQ) \\\u003C93.8 indicates aphasia.\n6. Possess a certain level of auditory comprehension and can tolerate research examinations lasting 0.5-1 hour.\n7. The subject and their legal guardian understand and consent to participate in this study and have jointly signed the informed consent form.\n\nExclusion Criteria:\n\n1. Moderate to severe dysarthria as assessed by the Frenchay Dysarthria Assessment.\n2. Severe speech apraxia or oral-facial apraxia.\n3. Significant anxiety or moderate to severe depressive symptoms as assessed by the Hamilton Anxiety and Depression Scales.\n4. Pre-stroke speech or language disorders.\n5. Severe systemic diseases such as cardiopulmonary diseases that cannot tolerate rehabilitation treatment or infectious diseases.\n6. Significant sleep disorders or mental disorders.\n7. Pregnant or lactating women.\n8. Contraindications for MRI examination (presence of metal foreign bodies or other implanted electronic devices in the body).","25 Years",{"count":225,"type":20},82,[23],"The aim of this clinical trial is to assess the therapeutic efficacy of acupuncture combined with neuromodulation techniques for the treatment of post-stroke aphasia and to explore the brain mechanisms involved. The study seeks to answer two primary questions: the effectiveness of the integrated intervention of acupuncture and repetitive transcranial magnetic stimulation (rTMS) on post-stroke aphasia, and the mechanisms underlying language function impairment and recovery.\n\nThe research is divided into two parts:\n\nPart One:\n\nParticipants will be randomized into two groups:\n\nGroup A: Receives low-frequency rTMS followed by high-frequency rTMS. Group B: Receives high-frequency rTMS followed by low-frequency rTMS.\n\nPart Two:\n\nParticipants will be randomized into four groups:\n\nrTMS Experimental Group: Individualized targets and intervention methods based on integrated fMRI and behavioral data. The rTMS intervention involves continuous treatment for two weeks, 5 sessions per week, each lasting 10-25 minutes, at 80% of the active motor threshold (AMT).\n\nrTMS Control Group: Standard rTMS protocol guided by clinical recommendations, with continuous treatment for two weeks, 5 sessions per week, each 20 minutes, at 80% AMT.\n\nElectroacupuncture Group: Points include Speech Area 1 (Yan Yu Yi Qu 1), Speech Area 2 (Yan Yu Yi Qu 2), Fengchi (Fengchi, GB20), Tiantu (Tiantu, CV22), Tongli (Tongli, HT5), Lianquan (Lianquan, CV23), and Paralianquan (Pang Lianquan). After needle insertion and obtaining Qi, electrical stimulation is applied with a discontinuous wave at 2Hz, at a tolerable intensity for the patient, for 30 minutes each session.\n\nCombined rTMS and Electroacupuncture Group: Combines both intervention methods as described above.",[229],"Aphasia, Rehabilitation","2024-07-09",{"date":232,"type":33},"2024-07-10",{"date":234,"type":33},"2020-06-01",{"date":236,"type":20},"2025-01",{"name":39,"class":40},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":15,"minAge":245,"maxAge":17,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100551689","clinical-study-of-trilinolein-cream-for-prevention-of-relapse-in-remission-of-moderate-to-severe-atopic-dermatitis-100551689","NCT06463353","Clinical Study of Trilinolein Cream for Prevention of Relapse in Remission of Moderate-to-severe Atopic Dermatitis.","A Multicenter, Randomized, Double-blind, Controlled Clinical Study of Xia's Dermatology Method of Nourishing Blood and Moistening Dryness to Prevent Relapse in Remission of Moderate-to-severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Patients with a clear diagnosis of atopic dermatitis in accordance with the diagnostic criteria of Chinese and Western medicine;\n2. Age ≥2 years and ≤75 years; gender is not limited;\n3. Patients with a previous history of moderate to severe atopic dermatitis (EASI score ≥ 8, or SCORAD score ≥ 26, or IGA score ≥ 3);\n4. Patients were in AD remission with a skin lesion IGA score ≤ 1 for 2 consecutive weeks;\n5. All patients or guardians signed an informed consent form, of which the guardian signed the informed consent form for patients aged 2-8 years (\\\u003C8); the patient and guardian signed the informed consent form for patients aged 8-18 years (\\\u003C18); and the patient signed the informed consent form for patients aged 18-75 years.\n\nExclusion Criteria:\n\n1. Patients who are in the acute morbid stage and have erosion, exudation, and secondary infection;\n2. Patients who are allergic to the test article and its components;\n3. Patients who are currently participating in other clinical studies or have participated in other clinical studies within 1 month;\n4. Patients with skin diseases other than AD in the area to be treated;\n5. Patients with severe hepatic or renal diseases, hematologic disorders, autoimmune diseases, chronic severe infections, diabetes or diseases of God, drug or alcohol abuse;\n6. Suffering from malignant tumors or other serious diseases that may affect the correct assessment of efficacy;\n7. Have been treated with dupliyuzumab with a discontinuation time ≤ 12 weeks, or have been treated with a JAK inhibitor with a discontinuation time ≤ 1 week;\n8. Patients who have been systematically treated with hormones, other immunosuppressive agents (cyclosporine, methotrexate, reglanoside, etc.) or phototherapy;\n9. Other reasons (e.g., poor compliance, inability to follow up as scheduled) that the investigator believes preclude enrollment.","2 Years",{"count":247,"type":20},376,[23],"This multicenter, randomized, double-blind, placebo-controlled will be conducted at Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine; Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine; Jiading District Hospital of Traditional Chinese Medicine, Shanghai; and Baoshan District Hospital of Integrative Medicine, Shanghai; Huashan Hospital affiliated with Fudan University, Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, and the First Affiliated Hospital of the Naval Medical University. Approximately 376 participants will be recruited and randomly assigned to the Trilinolein cream or cream base group using block group randomization. The primary outcome will be time to relapse (number of days from the start of dosing to the time of relapse rating), and secondary outcomes will include eczema area and severity indices, overall investigator ratings, visual itch analog scores, dermatologic quality of life indices, overall improvement rates, and safety metrics. All data from the study will be analyzed using the SPSS 23.0 statistical package.",[84],"2024-06-12",{"date":253,"type":33},"2024-06-17",{"date":255,"type":20},"2024-06-15",{"date":257,"type":20},"2027-11-30",{"name":39,"class":40},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":266,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":68},"100528831","the-relationship-between-moderate-to-severe-psoriasis-and-sleep-disturbance-100528831","NCT06165887","The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance","The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance: a Prospective Cohort Study","Inclusion Criteria:\n\n1. In line with the diagnostic criteria of psoriasis\n2. PASI\\>10 or BSA\\>10%\n3. Understand and agree to participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Those with serious mental diseases, such as depression, anxiety, etc;\n2. PSQI\\>5 points;\n3. Long term use of sedative and hypnotic drugs;\n4. Patients with diabetes mellitus or severe heart, liver and kidney disease;\n5. Those diagnosed with sleep disorders, such as apnea syndrome, periodic limb movement disorder, restless legs syndrome, narcolepsy, etc;\n6. There are serious cardiovascular and cerebrovascular diseases, respiratory system diseases, and immune system diseases;\n7. Pregnant women during pregnancy, lactation, or planned trials;\n8. Those who have participated in other clinical studies or are participating in other clinical trials within 3 months;\n9. Unable to cooperate with the study for any reason, such as the following situation: language understanding, unable to complete the scale tester.\n\nIf any one of the above items is met, it shall be excluded.",{"count":267,"type":20},156,"Psoriasis is a common chronic and systemic immune-mediated disease, induced by a combination of genetic and environmental effects. The increasingly worrying question is the negative impact on patients' sleep, which has become an important comorbidity of psoriasis. To investigate the causal relationship between psoriasis and sleep status, a prospective cohort study will be conducted by separating moderate-to-severe psoriasis patients and healthy individuals into distinct cohorts in order to observe their sleep status.",[270],"Moderate-to-severe Psoriasis","2024-02-20",{"date":273,"type":33},"2024-02-21",{"date":275,"type":20},"2024-02",{"date":277,"type":20},"2026-06",{"name":39,"class":40},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":75,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":285,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":68},"100514954","cohort-study-of-inpatients-and-outpatient-patients-with-cerebral-small-vessel-disease-100514954","NCT05985213","Cohort Study of Inpatients and Outpatient Patients With Cerebral Small Vessel Disease","Inclusion Criteria:\n\n1. Participants aged between 18 and 80 years, with no restriction on gender.\n2. Participants who have completed a 3.0T MRI of the head within one year at Yueyang Hospital, and meet the imaging diagnostic criteria of the 2013 STRIVE guidelines.\n3. Participants who have a Modified Rankin Scale (mRS) score of 0-2 (able to perform activities of daily living) at the time of the visit.\n4. Participants who are able to understand and agree to participate in the study, and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Diagnosis of symptomatic lacunar syndrome without 6 months of onset (participants can be enrolled after 6 months to avoid the impact of the acute phase).\n2. Intracranial and extracranial vascular examination confirms stenosis of the blood vessel by ≥50%.\n3. Imaging data reveals intracranial space-occupying lesions.\n4. A history of other neurological or mental illnesses with a definite diagnosis of the cause, including stroke (excluding lacunar infarctions), neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease).\n5. Co-occurring serious illnesses, such as malignant tumors, heart failure, respiratory failure, renal failure, severe liver dysfunction, severe blood system diseases, or gastrointestinal bleeding.\n6. Severe impairment in vision, hearing, language function, or limb muscular weakness that prevents completion of relevant tests.\n7. Women who are pregnant or breastfeeding.\n8. MRI scan contraindicated due to various reasons (such as claustrophobia).\n9. Any other reasons that prevent the collection of clinical data required for this study.",{"count":286,"type":20},1078,"This cohort study involves the dynamic collection of clinical information, including serum parameters , blood pressure variability, imaging data, and neuropsychological scales, in patients with cerebral small vessel disease (CSVD). The study aims to summarise the clinical and imaging characteristics of the CSVD population and identify novel CSVD risk factors. Additionally, this study intend to uncover the mechanisms underlying the clinical and imaging outcomes of CSVD. Furthermore, a multivariable prediction model for cognitive and mood disorders in patients with CSVD will be established.",[289],"Cerebral Small Vessel Diseases","2023-08-09",{"date":292,"type":33},"2023-08-14",{"date":294,"type":33},"2020-12-01",{"date":66,"type":20},{"name":39,"class":40},""]